Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Share News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.50
Bid: 3.00
Ask: 4.00
Change: -0.40 (-10.26%)
Spread: 1.00 (33.333%)
Open: 3.90
High: 0.00
Low: 0.00
Prev. Close: 3.90
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proteome Appoints Geoffrey Ellis As Finance Director, Loss Widens

Tue, 30th Sep 2014 09:41

LONDON (Alliance News) - Proteome Sciences PLC said Tuesday that has appointed Geoffrey Ellis as Finance Director, and posted a slightly widened pretax loss for the half-year to the end of June.

Ellis previously acted as chief financial officer of The Walt Disney Co's Network of Disney Channels in Europe, the Middle East and Africa, and managing director Disney Channel Scandinavia, Middle East and Emerging Markets.

Ellis succeeds James Malthouse, who is retiring after 20 years with the company.

Proteome posted a pretax loss of GBP2.1 million, widened from a loss of GBP1.9 million a year before, as revenue declined to GBP784,276 from GBP885,475, and administrative expenses rose slightly to GBP2.5 million from GBP2.3 million.

The company said following the growth in licensing, services and sales of its Tandem Mass Tag reagents in 2013, its core technologies had continued to strengthen in the first-half of 2014. Some contracts it was expecting were delayed, however, and the company said because of their size it is difficult to predict when they will come through.

Proteome said that whilst it is "difficult to be precise" over the timing of these revenue contributions, the scale and number of contracts in its order book is "growing steady and that performance is expected to continue in 2015."

Sales of Tandem Mass Tag reagent's rose 98% compared to the previous year. Proteome expects to see a more significant contribution from the products in the second-half, as well as continued improvement in its revenues from licences, sales and services.

Last Friday the company announced "excellent" results from in vitro toxicity tests for its two lead compounds to treat Alzheimer's disease, which it hopes will attract pharmaceutical companies to partner with Proteome on the treatments.

Shares in Proteome are trading down 8.0% at 35.18 pence Tuesday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
11 May 2018 08:38

Hargreaves Services Chairman To Step Down, Replacement Named

LONDON (Alliance News) - Hargreaves Services PLC said Friday that David Morgan has decided to step down as chairman and will be succeeded by Roger McDowell.Morgan, who has served as a since

Read more
24 Apr 2018 12:54

Proteome Sciences Appoints Chief Commercial Officer Dennis To Board

LONDON (Alliance News) - Proteome Sciences PLC on Tuesday appointed Chief Commercial Officer Richard Dennis to the board of directors.Dennis joined Proteome in April last year, having as an

Read more
24 Apr 2018 12:11

Proteome Sciences 2017 Loss Narrows On Revenue Growth And Cost Cuts

LONDON (Alliance News) - Life sciences firm Proteome Sciences PLC said Tuesday its annual loss narrowed in 2017 on higher revenue and lower costs, as it looks to focus growth on its biomarker loss

Read more
9 Feb 2017 11:14

Proteome Sciences trades in line as it consolidates lab facilities

(ShareCast News) - Proteome Sciences provided a trading update for the 12 months to 31 December on Thursday, saying that after a strong first half, progress continued throughout the rest of the year with results in line with expectations. The AIM-traded firm said buoyed by robust sales of its TMT re

Read more
9 Feb 2017 09:13

Proteome Sciences Expects Narrowed Loss, Appoints Commercial Officer

Read more
4 Jan 2017 16:48

DIRECTOR DEALINGS: Vehicle Of Proteome Non-Executive Buys Shares

Read more
31 Oct 2016 09:18

Proteome Sciences plunges after highly discounted placing

(ShareCast News) - After offering the shares at a highly discounted price before getting shareholder approval, Proteome Sciences has raised £3.3m through a placing and subscription of new shares to accelerate its strategy and meet client demand. The AIM-listed company issued the shares at 5p, a 45%

Read more
15 Sep 2016 10:34

Proteome Sciences shares slide as losses widen

(ShareCast News) - Proteome Sciences released its unaudited interim results for the six months to 30 June on Thursday, with revenues to 30 June increasing 32% to £1.12m. The AIM-traded company said revenue from licences, sales and services increased 44% to £1.08m during the period, while TMT reagent

Read more
16 Jun 2016 15:12

UK Shareholder Meetings Calendar - Next 7 Days

Read more
18 May 2016 08:24

Proteome Sciences Appoints New CEO As Annual Loss Narrows

Read more
5 Apr 2016 08:40

Proteome Sciences Welcomes Supportive Reports On Protein Profiling

Read more
29 Feb 2016 10:01

Proteome Sciences Starts 2016 Well, Production Capacity Up

Read more
5 Nov 2015 10:39

Proteome Sciences Gets Positive Results From CK1d Inhibitors Study

Read more
30 Sep 2015 09:15

Proteome On Track For Strong Second Half Revenue As Loss Narrows

Read more
17 Jul 2015 11:17

Proteome Sciences Expects Strong Revenue Growth On Good Pipeline

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.